The medtech SPAC scene seems to be going through one of its periodic lulls, with just one deal announced in August and one in September, Evaluate Vantage reports. The latter is the acquisition of Prenetics, a genomics and diagnostics testing company based in Hong Kong, by the Nasdaq-listed Artisan Acquisition. The deal values Prenetics at around $1.3 billion, not unreasonable considering its forecast 2021 revenues of $205 million.
Looking at the other end of the SPAC process, seven companies have closed their deals and now enjoy stock market listings. But their performance has been decidedly mixed. Read more.
